A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
2021 · Blood · 206 citations
https://doi.org/10.1182/blood.2020008936
Y
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
249
Papers
3.0K
Citations
32
h-index
75
i10-index
Yi Xiao is an academic researcher from Chinese Academy of Medical Sciences & Peking Union Medical College. The author has contributed to research in topics: CAR-T cell therapy research & Obstructive Sleep Apnea Research & Crystallization and Solubility Studies. The author has an h-index of 32, co-authored 212 publications.
ORCID: 0000-0001-7274-6774Papers by this author
worksAnti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
2018 · Journal of Hematology & Oncology · 61 citations
https://doi.org/10.1186/s13045-018-0672-7
High Risk Characteristics for Recurrent Cardiovascular Events among Patients with Obstructive Sleep Apnoea in the SAVE Study
2018 · EClinicalMedicine · 51 citations
https://doi.org/10.1016/j.eclinm.2018.09.002
Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
2020 · Clinical and Translational Medicine · 27 citations
https://doi.org/10.1002/ctm2.176
Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components
2025 · Small Methods · 16 citations
https://doi.org/10.1002/smtd.202401632
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
2022 · Experimental Hematology and Oncology · 15 citations
https://doi.org/10.1186/s40164-022-00323-9
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat